<SEC-DOCUMENT>0001209191-11-024915.txt : 20110428
<SEC-HEADER>0001209191-11-024915.hdr.sgml : 20110428
<ACCEPTANCE-DATETIME>20110428203417
ACCESSION NUMBER:		0001209191-11-024915
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110427
FILED AS OF DATE:		20110428
DATE AS OF CHANGE:		20110428

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			EMANUELE ROBERT MARTIN
		CENTRAL INDEX KEY:			0001184991

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32157
		FILM NUMBER:		11790477

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADVENTRX PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001160308
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841318182
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		8585520866

	MAIL ADDRESS:	
		STREET 1:		12390 EL CAMINO REAL
		STREET 2:		SUITE 150
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOKEYS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010928
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0203</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2011-04-27</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001160308</issuerCik>
        <issuerName>ADVENTRX PHARMACEUTICALS INC</issuerName>
        <issuerTradingSymbol>ANX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001184991</rptOwnerCik>
            <rptOwnerName>EMANUELE ROBERT MARTIN</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>12390 EL CAMINO REAL, SUITE 150</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92130</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Senior VP, Development</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>588663</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The reporting person acquired these securities on April 8, 2011 as consideration for the reporting person's interest in SynthRx, Inc., which ADVENTRX Pharmaceuticals, Inc., the issuer of these securities, acquired by merger on April 8, 2011. Of these 588,663 shares, (i) 42,035 shares are currently being held in escrow and are subject to forfeiture during 12-month period following the merger to satisfy claims arising as a result of SynthRx's breach of its representations and warranties or covenants in the merger agreement and (ii) 407,477 shares are subject to repurchase by the issuer at a purchase price of $0.001 per share in the event and to the extent of failure to achieve the first development milestone under the merger agreement.</footnote>
    </footnotes>

    <remarks>The terms of the merger agreement pursuant to which the issuer acquired SynthRx, Inc. provide that the former stockholders of SynthRx, including the reporting person, will receive additional shares of issuer common stock upon achievement of specified development milestones related to SynthRx's lead product candidate if issuance of such contingent, additional shares is approved by the issuer's stockholders by December 31, 2011. The value of such additional shares, if any, will be based on the 10-day volume weighted average of the closing prices of issuer common stock immediately prior to achievement of the applicable milestone. The reporting person's right to receive such additional shares pursuant to this earn-out right became fixed and irrevocable on April 8, 2011, the effective date of the merger.</remarks>

    <ownerSignature>
        <signatureName>/s/ R. Martin Emanuele</signatureName>
        <signatureDate>2011-04-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.3_375291
<SEQUENCE>2
<FILENAME>poa.txt
<DESCRIPTION>POA DOCUMENT
<TEXT>
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints
Patrick L. Keran and Brian M. Culley, acting alone or together, the
undersigned's true and lawful attorneys-in-fact to:

(1)    execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer, director and/or more than 10% stockholder of ADVENTRX
Pharmaceuticals, Inc. (the "Company"), Forms 3, 4 and 5 (including amendments
thereto) with respect to securities of the Company in accordance with Section
16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules
thereunder;

(2)    do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5 (or amendments thereto), and timely file such form with the United States
Securities and Exchange Commission and any stock exchange or similar authority;
and

(3)    take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, in connection
with filing such Form 3, 4 or 5, it being understood that the documents executed
by such attorneys-in-fact on behalf of the undersigned pursuant to this Power of
Attorney shall be in such form and shall contain such terms and conditions as
such attorneys-in-fact may approve in such attorneys-in-fact's discretion.

The undersigned hereby grants to such attorneys-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorneys-in-fact shall lawfully do or
cause to be done by virtue of this Power of Attorney and the rights and powers
herein granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act,
and that this Power of Attorney does not relieve the undersigned from
responsibility for compliance with the undersigned's obligations under the
Exchange Act. The undersigned further acknowledges that this Power of Attorney
authorizes, but does not require, the attorneys-in-fact to act in their
discretion on information provided to them without independent verification of
such information.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
attorneys-in-fact.



	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 27th day of April, 2011.


                                         /s/ R. Martin Emanuele
                                         R. Martin Emanuele
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
